MCP
TEVA icon

Militia Capital Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Militia Capital Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$2.87M Buy
92,000
+2,000
+2% +$49.3K 1.09% 17
2025
Q3 		$1.82M Buy
+90,000
New +$1.58M 0.84% 30

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Militia Capital Partners's TEVA Position: Q4 2025 in Review

Militia Capital Partners increased its Teva Pharmaceuticals (TEVA) stake by 2.2% in Q4 2025, buying an estimated $49.3K and bringing the position to 92,000 shares worth $2.87M. The position accounts for 1.09% of the portfolio, ranked #17.

Militia Capital Partners first reported a position in TEVA in Q3 2025 and has held it in 2 quarters since. 630 funds tracked by Wall St. Rank hold TEVA as of Q4 2025.

  • Militia Capital Partners held 92,000 shares of Teva Pharmaceuticals worth $2.87M as of Q4 2025.
  • Militia Capital Partners bought 2,000 Teva Pharmaceuticals shares in Q4 2025, an estimated $49.3K.
  • Teva Pharmaceuticals made up 1.09% of Militia Capital Partners's portfolio in Q4 2025, its #17 holding.
  • Militia Capital Partners first reported a position in Teva Pharmaceuticals in Q3 2025 and has held it in 2 quarters since.
  • 630 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2025.

Based on Militia Capital Partners's 13F filing for Q4 2025, filed 17 Feb 2026.